Category Archives: adult stem cell

Q Therapeutics’ and Invitrogen’s Symbiotic Relationship

Posted on February 25, 2008 by jrowley

Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic … Continue reading →

Posted in adult stem cell, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, MS, Neural Repair, Q Therapeutics, Regenerative Medicine, stem cells | Tagged , , , | 2 Comments

The Developing Embyronic Stem Cell Clinical Landscape

Posted on February 14, 2008 by jrowley

ES cell biopsy from blastocyst. Continue reading →

Posted in adult stem cell, Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, spinal cord injury, stem cells | Tagged , , , , | Leave a comment

Cytori Announces Progress in Cardiac Regeneration Clinical Studies

Posted on February 1, 2008 by jrowley

Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose … Continue reading →

Posted in adult stem cell, autologous, Bioprocessing, cardiac regeneration, cell delivery, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, patient specific cell therapy, personalized medicine, Regenerative Medicine, stem cells | Leave a comment

Osiris Scores $225M DoD Contract for Acute Radiation Syndrome Treatment with Prochymal Adult Stem Cell Product

Posted on January 12, 2008 by jrowley

Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued … Continue reading →

Posted in adult stem cell, business models, Clinical Trials, DoD, MSCs, Osiris, Regenerative Medicine, stem cells | Tagged , , , , , | 1 Comment

Celgene Strengthens Adult Stem Cell Patent Estate

Posted on January 4, 2008 by jrowley

I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last … Continue reading →

Posted in adult stem cell, Biomaterials, Celgene, Intellectual Property, placenta stem cells, Regenerative Medicine, stem cells | Tagged , , , , | 1 Comment

Osiris Releases 1 Year Data from Chrondrogen Trial

Posted on December 1, 2007 by jrowley

Osiris Therapeutics last week announced positive data that came out of their Phase I/II double blinded Chondrogen trial. They demonstrated statistically significant improvements in joint pain in patients with osteoarthritis, however this seems to be an about face compared to … Continue reading →

Posted in adult stem cell, Biomaterials, cartilage, Clinical Trials, orthopedics, Osiris, Regenerative Medicine, stem cells | 1 Comment

Athersys’ adult allogeneic stem cell IND gets OK from FDA

Posted on November 20, 2007 by jrowley

On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will … Continue reading →

Posted in adult stem cell, Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, stem cells | Tagged , , , | 1 Comment